Our objective is to investigate, from a holistic approach, the role of dietary polyphenols in the prevention of chronic-degenerative diseases. We want to understand the tremendous interindividual variability that we find in the metabolism and biological activity of polyphenols through the implication of genotype, ageing, sex, intestinal microbiota, obesity and various diseases. A central axis behind this variability is the existence of specific human metabolic phenotypes (metabotypes) derived from the microbiota, both by the singular metabolites that they produce and by the composition and functionality of said associated microbiota. We are currently investigating the association between specific metabotypes and intestinal dysbiosis as a predictive tool for obesity and diseases related to this dysbiosis.
Specifically, we aimed to:
- Evaluate the metabolism and biological activity of polyphenols in cardiovascular diseases, colorectal, prostate and breast cancer, obesity, metabolic syndrome, and Parkinson's disease (clinical trials, experimental animals and cell cultures).
- Characterise the two-way interaction between polyphenols and microbiota: Identification of new microbial metabolites and bacteria specifically involved in their synthesis.
- Identify the metabolic profiling of polyphenols-derived metabolites in tumour tissues of patients for the correct design of mechanistic studies.
- Evaluate the protection exerted by specific metabotypes of polyphenols associated with intestinal microbiota against cardiometabolic risk and cognitive impairment.